Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:07:53 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Q:CSLLY - CSL LTD SPON ADR EACH REPR 0.5 ORD - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CSLLY - Qnot subscribed89.60-0.56-0.626.32,33137889.31  89.86  89.023105.11  71.5115:59:59Apr 2415 min RT 2¢

Recent Trades - Last 10 of 378
Time ETExPriceChangeVolume
15:59:59Q89.86-0.301
15:56:17Q89.60-0.56100
15:56:17Q89.60-0.56100
15:56:06Q89.808-0.35218
15:54:55Q89.859-0.3016
15:52:34Q89.73-0.4314
15:46:32Q89.769-0.391284
15:46:11Q89.86-0.301,558
15:45:32Q89.73-0.43100
15:45:25Q89.73-0.4393

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-24 07:05U:CSLLYNews ReleaseTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-04-24 03:00U:CSLLYNews ReleaseCSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI(TM) (sparsentan) for the treatment of IgA Nephropathy
2024-03-19 07:00U:CSLLYNews ReleaseFerinject(TM) approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
2024-03-06 09:00U:CSLLYNews ReleaseCSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season
2024-02-23 07:06U:CSLLYNews ReleaseTravere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
2024-02-12 22:54U:CSLLYNews ReleaseHalf year reported NPATA US$2 billion ‚ ¹, ‚ ² Up 13% at constant currency ‚ ³
2024-02-11 17:47U:CSLLYNews ReleaseCSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])
2024-02-05 08:30U:CSLLYNews ReleaseNew COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
2024-01-16 08:00U:CSLLYNews ReleaseHarris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
2024-01-03 08:00U:CSLLYNews ReleaseCSL Behring Announces Availability of Hizentra ‚ ® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics ¢ € ™ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-21 08:00U:CSLLYNews ReleaseCSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
2023-12-21 08:00U:CSLLYNews ReleaseCSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
2023-12-14 14:47U:CSLLYNews ReleaseCSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
2023-12-11 19:30U:CSLLYNews ReleaseCSL Behring's HEMGENIX ‚ ® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
2023-11-28 08:05U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
2023-11-28 08:00U:CSLLYNews ReleaseJapan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics ¢ € ™ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
2023-11-24 02:00U:CSLLYNews ReleaseIron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment